A phase IV, randomized, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety and tolerability of CSL Limited's influenza virus vaccine in adults aged greater than or equal to 18 to less than 65 years.

Trial Profile

A phase IV, randomized, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety and tolerability of CSL Limited's influenza virus vaccine in adults aged greater than or equal to 18 to less than 65 years.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Influenza virus vaccine (Afluria) (Primary)
  • Indications Influenza virus infections
  • Focus Therapeutic Use
  • Sponsors CSL; Seqirus
  • Most Recent Events

    • 29 Aug 2016 Results published in the Vaccine.
    • 24 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top